Welcome to our dedicated page for Candel Therapeutics SEC filings (Ticker: CADL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Candel Therapeutics, Inc. filings document a clinical-stage oncology company developing multimodal biological immunotherapies and reporting as a Nasdaq-listed issuer of common stock. Its proxy materials cover director elections, auditor ratification and annual-meeting voting matters, while Form 8-K reports furnish operating and financial results and research-and-development presentations.
Other filings disclose material agreements and capital-structure matters, including term-loan financing and facility lease amendments, along with clinical and regulatory disclosures tied to aglatimagene besadenovec and linoserpaturev. The filing record also reflects governance matters, shareholder voting mechanics and exhibit-based disclosures for key corporate actions.
Director Nicoletta Loggia of Candel Therapeutics (NASDAQ: CADL) reported the acquisition of 2,141 shares of common stock on June 25, 2025. The shares were purchased at $4.67 per share through a registered direct offering, resulting in a total investment of approximately $10,000.
The transaction was executed pursuant to a Securities Purchase Agreement dated June 23, 2025. Following the reported transaction, Loggia directly owns 2,141 shares of Candel Therapeutics common stock.
Key Transaction Details:
- Transaction Type: Direct Purchase through Registered Offering
- Share Price: $4.67
- Total Shares Acquired: 2,141
- Ownership Type: Direct
- Filing Date: June 28, 2025
Charles Schoch, Chief Financial Officer of Candel Therapeutics (CADL), reported acquiring 5,353 shares of Common Stock on June 25, 2025, at a price of $4.67 per share through a registered direct offering. The transaction was executed pursuant to a Securities Purchase Agreement dated June 23, 2025.
Following this transaction, Schoch's direct beneficial ownership increased to 43,391 shares. The acquisition was made through a registered direct offering, indicating a structured investment in the company by its CFO.
- Transaction Type: Direct Purchase (Form Code: A)
- Transaction Value: Approximately $25,000
- Ownership Form: Direct
- No derivative securities were involved in this transaction
Insider Trading Alert: Gary J. Nabel, Director of Candel Therapeutics (NASDAQ: CADL), acquired 5,353 shares of common stock on June 25, 2025, at a price of $4.67 per share. The total transaction value amounts to approximately $25,000.
The shares were acquired through a registered direct offering pursuant to a Securities Purchase Agreement dated June 23, 2025. Following the transaction, Nabel directly owns 5,353 shares of Candel Therapeutics.
This Form 4 filing, submitted on June 28, 2025, represents a direct purchase of shares by a company insider, potentially signaling confidence in the company's prospects. The transaction was executed through an attorney-in-fact, Charles Schoch, who signed the filing on Nabel's behalf.
Candel Therapeutics Chief Scientific Officer Francesca Barone acquired 4,282 shares of common stock on June 25, 2025, through a registered direct offering at a price of $4.67 per share. The transaction was executed pursuant to a Securities Purchase Agreement dated June 23, 2025.
Following this acquisition, Barone now directly owns 100,809 shares of the company's common stock. The Form 4 filing indicates this was a direct ownership transaction, with no derivative securities involved.
- Transaction Type: Registered Direct Offering Purchase
- Total Transaction Value: $19,996.94
- Filing Status: Individual filing by reporting person
- Position: Chief Scientific Officer (Executive Officer)
Insider Trading Alert: Joseph C. Papa, Director of Candel Therapeutics (NASDAQ: CADL), acquired 64,239 shares of common stock on June 25, 2025, through a registered direct offering at $4.67 per share. The transaction was executed through the Joseph C. Papa Revocable Living Trust.
Key Transaction Details:
- Total shares acquired: 64,239 shares
- Purchase price: $4.67 per share
- Transaction value: approximately $300,000
- Post-transaction holdings: 64,239 shares (indirect) + 38,032 shares (direct)
The acquisition was made pursuant to a Securities Purchase Agreement dated June 23, 2025. The shares are held indirectly through a trust arrangement, with Papa serving as trustee. This insider purchase may signal management's confidence in the company's prospects.
Candel Therapeutics, Inc. (CADL) – Form 4 filing dated 06/24/2025
The company’s Chief Financial Officer, Charles Schoch, reported the grant of a stock option for 50,000 shares of common stock with an exercise price of $4.75 per share. The option was issued on 06/20/2025 and will expire on 06/20/2035.
Vesting schedule: 25 % of the award vests on 06/20/2026; the remaining 75 % vests in 36 equal monthly installments thereafter, contingent on continued service.
Following this transaction, Mr. Schoch beneficially owns 50,000 derivative securities (stock options) directly. No open-market purchases or sales of CADL common shares were disclosed.
Candel Therapeutics has announced a registered direct offering of 3,221,395 shares of common stock at $4.67 per share, expected to raise approximately $15.0 million in gross proceeds. The offering price equals the closing price reported on Nasdaq Global Market on June 23, 2025.
Key details of the offering include:
- Purchasers include existing healthcare-focused institutional investors, executive officers, and directors
- Offering is made under shelf registration statement (File No. 333-266605) declared effective August 12, 2022
- Closing anticipated for June 25, 2025, subject to customary conditions
The company, an emerging growth company, is conducting this offering to strengthen its financial position. The securities purchase agreement was signed on June 23, 2025, with shares being offered through a registered direct offering structure. This strategic financing move involves both institutional and insider participation, potentially signaling management's confidence in the company's prospects.